Clinical significance of stem cell marker CD133 expression in colorectal cancer

Bin-Bin Wang¹, Zhi-juan Li², Feng-Feng Zhang¹, Hai-Tao Hou¹, Jing-Kui Yu¹ and Feng Li¹
Departments of ¹General Surgery and ²Gastroenterology, The Center People’s Hospital of Shandong Tengzhou, Tengzhou, Shandong Province, China

Summary. Objective: CD133, a glycoprotein, is expressed in different types of human stem cells and tumor cells. Detection of altered CD133 expression in colorectal cancer tissues could be useful as a marker for the prediction of colorectal tumorigenesis, progression, and prognosis. Methods: A total of 19 fresh and 145 paraffin-embedded tissue specimens from colorectal cancer patients were obtained for detection of CD133 expression using flow cytometry and immunohistochemistry, respectively. The tumorigenic capacity of tumor cells from 19 patients was assessed in nude mice. Association of CD133 expression was then analyzed for clinical significance. Results: The percentage of CD133-positive (CD133⁺) tumor cell population ranged between 0.84% and 16.75% (mean ratio=7.15%) of tumor cells in the 19 freshly isolated tissue samples. CD133 expression in tumor cells was associated with tumor lymph node metastasis (9.81% vs. 3.22%; p=0.013) and poor tumor differentiation (8.32% vs. 5.07%; p=0.043). In the 145 paraffin-embedded samples, CD133⁺ colorectal cancer was also associated with local recurrence of tumorigenesis (p=0.035) and distant metastasis (p=0.017), while patients with over 5% CD133⁺ tumor cells exhibited a decreased survival rate (p=0.001). Multivariate COX analysis showed that the depth of tumor invasion, histology, stages, lymph node metastasis, and CD133 expression were all independent prognosis factors for colorectal cancer (p=0.032, 0.011, 0.001, 0.002, and 0.030, respectively). Furthermore, as few as 5,000 CD133⁺ colorectal cancer HCT116 cells were sufficient to form tumor xenografts, whereas 1x10⁵ CD133⁺ tumor cells failed to develop tumor xenografts in nude mice. Conclusions: CD133 expression is a useful biomarker for prediction of colorectal cancer progression and survival of patients.

Key words: Colorectal cancer, Cancer stem cells, Tumorigenesis, CD133, Prognosis

Introduction

Colorectal cancer is one of the most significant malignancies worldwide, accounting in 2008 for over 1.2 million new cancer cases and 608,700 cancer-related deaths (Jemal et al., 2011). Risk factors for colorectal cancer include high-fat diet, consumption of smoked foods, red meat, tobacco and alcohol products, physical inactivity, and obesity. In contrast, consumption of high fiber foods, fruits and vegetables is thought to reduce the risk of colorectal cancer. Moreover, persons with a family history of colorectal cancer, inflammatory bowel disease, or adenomatous polyps have an increased risk of developing colorectal cancer (Jemal et al., 2011).

Advances in basic research and clinical management have resulted in early detection, prevention, and improved therapeutic options for patients with colorectal cancer. These major advances, including surgical procedures, chemotherapy, radiotherapy and immunotherapy have markedly improved the survival rate of colorectal cancer patients. However, there are still many patients who die of the disease because of complications related to tumor recurrence and metastasis, or resistance to chemoradiotherapy. Although these complications are thought to be due to the presence of cancer stem cells,
CD133 in colorectal cancer

further investigation of the underlying mechanism(s) of colorectal cancer recurrence and metastasis will aid in the development of novel strategies to effectively control this disease (Lapidot et al., 1994; Bonnet and Dick, 1997; Jin et al., 2004).

Cancer stem cells are a small number of tumor cells that have the ability to generate daughter tumor cells that self-renew and maintain tumor phenotypes (Lapidot et al., 1994; Bonnet and Dick, 1997; Jin et al., 2004). Cancer stem cells were successfully isolated and identified in some solid tumors, such as breast cancer (Al-Hajj et al., 2003), brain cancer (Singh et al., 2004), rectal cancer (O’Brien et al., 2007; Ricci-Vitiani et al., 2007), prostate cancer (Richardson et al., 2004; Collins et al., 2005), or lung cancer (Kim et al., 2004). O’Brien et al. showed that all colorectal stem cells were CD133+ and that the colorectal cancer cells of CD133+ subpopulation had a strong tumorigenic ability (O’Brien et al., 2007). Indeed, CD133 is a glycoprotein that is expressed in different types of human stem cells, including hematopoietic cells, endothelial progenitor cells, neuronal and glial cells, mammary glands, and digestive tract and tumor stem cells (such as glioblastoma and colorectal cancer) (Horn et al., 1999; Corbeil et al., 2000; Sanai et al., 2003; Shmelkov et al., 2005; Singh et al., 2005; Mizrak et al., 2008). Therefore, in this study, we examined changes in CD133 expression in colorectal cancer tissues. We then confirmed the tumorigenic potential of CD133+ colorectal cells in nude mice. Our study advances the development of CD133 as a marker for prediction of colorectal tumorigenesis, progression, and prognosis and for future target therapy of colorectal cancer patients.

Materials and Methods

Study population

In the present study, we prospectively recruited 19 patients with histologically confirmed colorectal cancer from the Surgical Oncology Service of China Medical University. Patients were recruited in the time period between October 2012 and September 2013 for flow cytometry identification of CD133+ tumor cells. These patients did not receive any adjuvant therapy, such as chemotherapy or radiotherapy before undergoing surgery. We then respectively obtained 145 cases of colorectal cancer tissue specimens that covered dates between January 2005 and December 2008 for immunohistochemical analysis of CD133 expression. The 145 patients from whom these samples were obtained met the following inclusion criteria. They had: 1) surgically resected tumor; 2) more than 10 pathologically examined lymph nodes; 3) available medical records; 4) documented informed consent; and 5) follow-up data. This study was approved by our institutional ethics and all patients consented to this study.

Flow cytometry analysis of CD133+ tumor cells

Fresh colorectal cancer tissue (1 cm³ per specimen) was obtained from the operating room and placed in a sterile specimen tube containing Gibco® RPMI 1640 medium and then transported to the laboratory on ice within 15 min. Next, the tissue specimens were cut into 1 mm³ pieces, which were subsequently digested with collagenase III (Sigma, St Louis, MO, USA) in dissociation flasks at 37°C for 1 h and then filtered through a 45-μm nylon mesh and washed twice with phosphatebuffered saline (PBS). After that, the cells were stained with Trypan blue to identify and remove dead cells, and cell numbers were counted under an inverted microscope. Cells were subsequently transferred to a 5-ml tube, washed twice with HBSS with 2% heat-inactivated calf serum (HICS) 5 min each by centrifuging at 1,000 rpm, re-suspended in 100 μl (1x10⁶ cells) of HBSS with 2% HICS. A 5 μl volume of Sandoglobulin solution (1 mg/ml) was added into the cell solution and incubated on ice for 10 min and further incubated with anti-CD2, -CD3, -CD10, -CD16, -CD18, and -CD31 antibodies (BD PharMigen, San Diego, USA) for 20 min on ice and subsequently incubated with a secondary antibody for 20 min and with 1 μl of streptavidin, conjugated with the indicated fluorescent dye, for an additional 20 min. These cell samples were subjected to flow cytometry using a FACSVantage machine (Facscalibur, BD, San Jose, CA, USA). Cells were routinely sorted twice, and reanalyzed for CD133+ cell purity, which typically was >95%. Dead cells were eliminated by using the viability dye 7AAD and CD133+/CD326+ tumor cells were selected by using anti-CD133 and CD326 antibodies. Similarly, we also sorted colorectal cancer HCT116 cells using flow cytometry.

Immunohistochemistry

Colorectal tissue specimens were fixed in formalin and embedded into paraffin blocks, and 4 μm-thick sections were prepared on glass slides precoated with 3-aminopropyl triethoxysilane for immunohistochemistry. Tissue samples were stained with hematoxylin and eosin to determine histological type and grade of tumors. For immunohistochemistry, we followed a previous study with minor modifications (Al-Rawi et al., 2004). Briefly, the sections were de-waxed in xylene and rehydrated in a series of gradient alcohol and washed with PBS. After that, the sections were blocked in 3% H₂O₂ for 30 min and incubated with normal serum for 30 min and then incubated with the primary antibody for 60 min (all at
room temperature). Next, sections were washed three times then incubated with the biotinylated secondary antibody (Multilink swine anti-goat/mouse/rabbit immunoglobulin, Dako Inc. Carpinteria, CA, USA) for 30 min and subsequently with an avidin-biotin complex at a dilution of 1:1000 (Vector Laboratories Ltd., city, CA, USA) for an additional 30 min at room temperature. The immunoreactive products were visualized by catalysis of 3, 3-diaminobenzidine (DAB) with horseradish peroxidase in the presence of H₂O₂. The sections were then counterstained in Gill's Hematoxylin and dehydrated in ascending grades of methanol before clearing in xylene, and mounting with a coverslip. Stained tissue sections were reviewed and scored under a light microscope. Cells were considered as CD133⁺ if their cytoplasm or membrane was stained with brown particles. We utilized the Maeda method, i.e., at low magnification (× 40 to × 200) to find the highest area with the nest CD133-positive cancer cell ratio for ten selected fields (Maeda et al., 2008). We then counted 1000 tumor cells for CD133⁺ cells and calculated the ratio of CD133⁺ cells (100 cells were counted per area) using a high-power microscope lens (× 400). The proportion of CD133⁺ cells in tumor tissue was divided into two levels: <5% vs. ≥5% of CD133⁺ expression.

**Nude mouse xenograft assay**

A total of 40 mice (4-8 week old NOD/SCID immunodeficient mice) were randomly divided into 2 groups that received: 1) 5,000 CD133⁺ colon cancer HCT116 cells or 2) 1x10⁶ CD133⁻negative HCT116 cells. The flow cytometry-sorted CD133⁺ and other cell populations were suspended in 1640/Matrigel (1:1 volume) and then subcutaneously injected into the flank region of the nude mice. The mice were then observed twice a week over a period of 56 days for tumor xenograft formation and growth.

**Statistical analyses**

Data were analyzed using SPSS13.0 statistical software (SPSS, Chicago, IL, USA). The student t-test and chi-square test were performed to generate p value for association of CD133⁺ levels with clinicopathological data form the patients. Kaplan-Meier curves and the Log rank method were used to analyze survival of patients stratified by CD133⁺ and a COX model was used to analyze prognosis factors.

**Results**

**Association of ratio of CD133⁺ cells with biological behaviors of colorectal cancer**

We first analyzed CD133 expression in 19 freshly isolated tissue specimens using flow cytometry and found that CD133 protein was expressed in 0.84% - 16.75 % of tumor cells in each case, with an average of 7.15%. CD133⁺ was associated with tumor lymph node metastasis (9.81% vs. 3.22%, p=0.013; Fig. 1 and Table 1) and tumor differentiation (8.32% vs. 5.07%, p=0.043; Table 2).
Table 1.

CD133+ status associated with clinicopathological data from colorectal cancer patients

We then confirmed the data on 145 colorectal cancer tissue specimens using immunohistochemistry and found that CD133 expression was expressed in the cell membrane and cytoplasm of more than 5% of tumor cells in 52 cases (35.86%) and in 93 (64.14%) specimens with less than 5% of tumor cell positivity (Fig. 2A,B).

CD133 expression was significantly associated with the presence of tumor lymph node metastasis and differentiation grade (Table 2). Moreover, CD133+ tumors had a high occurrence rate of the local recurrence and distant metastasis (P=0.035 and 0.017, respectively; Table 2). However, CD133 expression was not associated with age, gender, depth of tumor invasion or tumor stage (Table 2).

Association of CD133 expression with prognosis of colorectal cancer

Of the 145 colorectal cancer patients who were followed, 138 had complete records, resulting in a CCP follow-up rate of 95.17%, with an average follow-up time of 51.71 months. Tumors composed of ≥5% CD133+ tumor cells were associated with poorer postoperative survival compared to those composed of <5% CD133+ tumor cells (p=0.001, Fig. 3A). However, well differentiated colorectal cancer cases with ≥5% CD133+ tumor cells vs. <5% CD133+ tumor cells had no survival difference (p=0.153). In contrast, poorly differentiated colorectal cancer with ≥5% CD133+ tumor cells vs. <5% CD133+ tumor cells had significantly worse survival (p=0.004). Moreover, non-lymph node metastasized colorectal cancer with ≥5% CD133+ tumor cells vs. <5% CD133+ tumor cells had a worse survival rate (p=0.001). Similarly, lymph node metastasized colorectal cancer with ≥5% CD133+ tumor cells had a worse survival rate (p=0.001).
colorectal cancer with ≥5% CD133+ tumor cells vs. <5% CD133+ tumor cells had a worse survival rate (p=0.002; Fig. 3B).

We then performed a multivariate COX analysis and found that the depth of tumor invasion, histological grade, Dukes stage, lymph node metastasis, and CD133+ were all independent prognostic factors for prognosis of colorectal cancer (p=0.032, 0.011, 0.001, 0.002, and 0.030, respectively; Table 3).

**In vivo tumorigenicity of CD133+ HCT116 cells in a nude mouse xenograft model**

To confirm that CD133+ cells are indeed the cancer stem cell population, we sorted colorectal cancer HCT116 cells using flow cytometry. We then inoculated 5,000 CD133+ cells into nude mice. As a negative control, we subcutaneously injected 1x10^5 CD133-negative HCT116 cells into the flank region of nude mice. After a 6-10 week observation period, CD133+ tumor cells had formed a larger tumor lesion in 2 of 4 mice (Fig. 4A), whereas CD133-negative HCT116 cells failed to form tumor lesions (0 of 4 mice). Finally, 1x10^6 unsorted HCT116 cells formed xenograft tumors in 2/4 nude mice (Fig. 4B).

**Discussion**

Cancer stem cells are a small group of tumor cells that have the ability to generate daughter tumor cells and to self-renew in a manner that helps maintain the tumor phenotype (Lapidot et al., 1994; Bonnet and Dick, 1997; Jin et al., 2004). To date, numerous studies have implicated cancer stem cells in tumor resistance to chemo- and radiation therapy, as well as tumor recurrence and metastasis (Stingl, 2006; Li et al., 2008). Indeed, identification of cancer stem cells has become a very important task for the research community, as it may lead to a better understanding of tumorigenesis and aid in the development of novel targets for treatment or early detection and prevention of human cancers. In the current study, we first analyzed the expression of a cancer stem cell marker (CD133) in colorectal cancer tissues for association with colorectal tumorigenesis, progression, and prognosis. We then assessed the role of CD133 in xenograft formation and growth in nude mice.

### Table 3. Multivariate COX regression analysis of independent prognostic factors for colorectal cancer.

<table>
<thead>
<tr>
<th>Clinicopathological features</th>
<th>Risk ratio</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.103</td>
<td>0.539-2.842</td>
<td>0.546</td>
</tr>
<tr>
<td>Sex</td>
<td>1.042</td>
<td>0.725-2.455</td>
<td>0.439</td>
</tr>
<tr>
<td>Depth of invasion</td>
<td>1.257</td>
<td>1.015-2.624</td>
<td>0.032</td>
</tr>
<tr>
<td>Histological grade</td>
<td>1.902</td>
<td>1.655-3.673</td>
<td>0.011</td>
</tr>
<tr>
<td>Dukes stage</td>
<td>3.416</td>
<td>2.112-7.591</td>
<td>0.001</td>
</tr>
<tr>
<td>Lymphovascular invasion</td>
<td>2.165</td>
<td>1.692-4.839</td>
<td>0.002</td>
</tr>
<tr>
<td>CD133+ tumor cell ratio</td>
<td>1.678</td>
<td>1.094-2.941</td>
<td>0.030</td>
</tr>
</tbody>
</table>

**Fig. 2.** Immunohistochemical detection of CD133 expression in colorectal cancer tissues. **A.** CD133+ was expressed in more than 5% of tumor cells. **B.** CD133+ was expressed in less than 5% of tumor cells. A, B, x 400
Our data indicated that CD133 expression in tumor cells was associated with tumor lymph node metastasis, poor differentiation, tumor local recurrence, and distant metastasis. The multivariate COX analysis showed that depth of tumor invasion, histology, stages, lymph node metastasis, and CD133 expression were all independent prognostic factors for colorectal cancer. Furthermore, CD133+ colorectal cancer HCT116 cells had a greater potential to form tumor xenografts compared to CD133– tumor cells or even parental cancer cells in nude mice. Thus, detection of CD133 expression is a useful biomarker for prediction of colorectal cancer progression and survival of patients and indeed may be a novel target for control of colorectal cancer in the future.

Previous studies also investigated CD133+ tumor cells in colorectal cancer tissues or cell lines. For example, Yang et al assessed the level of CD133+ tumor cells and showed that different colorectal cancer cell

![Figure 3](image1.png)

**Fig. 3.** Kaplan-Meier curves stratified by CD133 expression in colorectal cancer cells. **A.** Overall survival of patients stratified by CD133+ tumor cell population (p=0.001). **B.** Overall survival of patients stratified by CD133+ tumor cell population and lymph node metastasis (p=0.002).

![Figure 4](image2.png)

**Fig. 4.** The nude mouse xenograft assay. **A.** CD133+ colorectal cancer HCT116 cells formed xenograft tumor in mice, whereas CD133-negative HCT116 failed to form tumor lesions. **B.** Unsorted colorectal cancer HCT116 cells formed xenograft tumors in mice.
lines have different levels of CD133 expression (Yang et al., 2011). Other studies showed that CD133 expression in colorectal cancer tissues was associated with clinical biological behaviors in colorectal cancer (Choi et al., 2009; Li et al., 2009). Li et al. showed that high CD133+ tumor cell ratio is an independent prognostic factor in colorectal cancer, although CD133+ ratio of tumor cells was not associated with clinicopathological features of colorectal cancer (Li et al., 2009). Choi et al. showed that CD133 expression was associated with male patients and colorectal cancer T stage (Choi et al., 2009). Our current findings are partially consistent and extend these earlier observations. In our present study, we used two sets of tissue samples with two different detection methodologies to assess CD133 expression in colorectal cancer tissues. We found that CD133 expression was associated with tumor lymph node metastasis, poor differentiation, tumor local recurrence, and distant metastasis. The multivariate COX analysis showed that CD133 expression was an independent prognostic factor for colorectal cancer. Our current study confirmed previous findings in other cancer types (Zhang et al., 2007; Beier et al., 2008; Song et al., 2008; Zeppernick et al., 2008). Of note, however, a report by Kojima et al. showed no correlation between CD133 expression and colorectal cancer prognosis (Horst et al., 2008). This difference may be due to the lack of tumor stage and small sample size in that study (Horst et al., 2008).

Indeed, one of the methods used to identify cancer stem cells is to verify their biological characteristics including self-renewal, proliferation, and differentiation (Jin et al., 2004; Kojima et al., 2008). In animal experiments, we were able to test the tumorigenicity of cancer stem cells or certain cancer stem cell marker-positive cells. In our current study, for example, as few as 5,000 CD133+ colorectal cells could generate nude mouse tumor xenografts, whereas 1x10^5 CD133- negative tumor cells failed to produce tumorigenesis. Similarly, O’Brien et al. and Ricci-Vitiani et al. showed that the CD133+ subpopulation of colon cancer cells could produce tumor xenografts in nude mice, but the capability and efficiency of different tumor specimens in generating xenograft tumors was variable (O’Brien et al., 2007; Ricci-Vitiani et al., 2007). These data suggest that besides CD133, other proteins or markers may be needed to identify colorectal cancer stem cells. Furthermore, in an in vitro study, Li et al. demonstrated that colorectal cancer stem cells could generate more primitive progenitor cells in serum-free three-dimensional cultures and maintain undifferentiated state growth and self-renewal cell populations (Li et al., 2008). Thus, the search for novel cancer stem cell markers could further help identify and verify cancer stem cells (Shmelkov et al., 2008). Finally, our current study has a notable limitation that requires mention. Specifically, we generated nude mouse tumor xenografts using a colorectal cancer cell line, and not CD133+ tumor cells from patients.

Acknowledgements. This study was supported in part by a grant from the China national natural science foundation (#30772100). We thank Medjaden bioscience limited for assisting in the preparation of this manuscript.

Conflict of interest statement. The authors declared that there is no conflict of interest in this work.

References


Accepted October 7, 2015